Linden Advisors’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Linden Advisors’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-381,300	Closed	-$3.91M	–	407
2023 Q2	$3.91M	Hold	381,300	–	–	0.04%	196
2023 Q1	$3.86M	Hold	381,300	–	–	0.04%	204
2022 Q4	$3.8M	Hold	381,300	–	–	0.04%	239
2022 Q3	$3.7M	Hold	381,300	–	–	0.03%	278
2022 Q2	$3.69M	Hold	381,300	–	–	0.03%	295
2022 Q1	$3.7M	Buy	+381,300	New	+$3.68M	0.02%	386

Linden Advisors's DALS Position: Q3 2023 in Review

Linden Advisors sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q3 2023, closing a stake of 381,300 shares — an estimated $3.91M sold.

Linden Advisors first reported a position in DALS in Q1 2022 and held it in 6 quarters. The position peaked at $3.91M in Q2 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

Linden Advisors reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Linden Advisors sold 381,300 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q3 2023, an estimated $3.91M.
Linden Advisors first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q1 2022 and held it in 6 quarters.
Linden Advisors's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $3.91M in Q2 2023.
0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q3 2023.

Based on Linden Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.